Scenesse European Union - English - EMA (European Medicines Agency)

scenesse

clinuvel europe limited - afamelanotide - protoporphyria, erythropoietic - emollients and protectives - prevention of phototoxicity in adult patients with erythropoietic protoporphyria (epp).

SCENESSE afamelanotide (as acetate) 16 mg implant vial Australia - English - Department of Health (Therapeutic Goods Administration)

scenesse afamelanotide (as acetate) 16 mg implant vial

clinuvel pharmaceuticals ltd - afamelanotide acetate, quantity: 18 mg - implant - excipient ingredients: polyglactin - scenesse is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (epp)

SCENESSE- afamelanotide implant United States - English - NLM (National Library of Medicine)

scenesse- afamelanotide implant

clinuvel inc. - afamelanotide (unii: qw68w3j66u) (afamelanotide - unii:qw68w3j66u) - scenesse® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp). none.

SCENESSE- afamelanotide implant United States - English - NLM (National Library of Medicine)

scenesse- afamelanotide implant

csm clinical supplies management europe gmbh - afamelanotide (unii: qw68w3j66u) (afamelanotide - unii:qw68w3j66u) - scenesse® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp). none. the safety and effectiveness of scenesse have not been established in pediatric patients. there were 10 subjects 65 years old and over in the clinical studies for epp [see clinical studies (14)]. of the 125 subjects treated with scenesse in these studies, 4 (3%) were 65 years of age and older. clinical studies of scenesse did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

OLICLINOMEL N7-1000 E 2500 mL IV emulsion for infusion with electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n7-1000 e 2500 ml iv emulsion for infusion with electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: glycerol; sodium hydroxide; ascorbyl palmitate; egg lecithin; sodium oleate; water for injections - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N7-1000 2500mL IV emulsion for infusion without electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n7-1000 2500ml iv emulsion for infusion without electrolytes bag

baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: water for injections; egg lecithin; ascorbyl palmitate; sodium hydroxide; glycerol; sodium oleate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N6-900 E 2500 mL IV emulsion for infusion with electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n6-900 e 2500 ml iv emulsion for infusion with electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: sodium hydroxide; ascorbyl palmitate; egg lecithin; water for injections; sodium oleate; glycerol - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N6-900 2500mL IV emulsion for infusion without electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n6-900 2500ml iv emulsion for infusion without electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: sodium hydroxide; ascorbyl palmitate; egg lecithin; water for injections; glycerol; sodium oleate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N5-800 E 2500 mL IV emulsion for infusion with electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n5-800 e 2500 ml iv emulsion for infusion with electrolytes bag

baxter healthcare pty ltd - soya oil; olive oil - injection, intravenous infusion - excipient ingredients: water for injections; egg lecithin; glycerol; sodium hydroxide; sodium oleate; ascorbyl palmitate - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLICLINOMEL N5-800 2500mL IV emulsion for infusion without electrolytes bag Australia - English - Department of Health (Therapeutic Goods Administration)

oliclinomel n5-800 2500ml iv emulsion for infusion without electrolytes bag

baxter healthcare pty ltd - olive oil; soya oil - injection, intravenous infusion - excipient ingredients: ascorbyl palmitate; water for injections; egg lecithin; sodium oleate; glycerol; sodium hydroxide - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.